&nbsp;

FrequentlyAskedQuestions-OCRSEERStat13.pdf

Jun 2023

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BORTDEXALENA+DARA; LENA+DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (Unfunded),

bortezomib (Unfunded),

lenalidomide (Unfunded),

dexamethasone

... Show more tags

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

BEACOPDAC(ESC)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

BEACOPDAC-14

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2023

Follow-Up of Self-Collected Human Papillomavirus (HPV) Testing

Document

FITKitInstructions-Slovak.pdf

Dec 2023

Document

FITKitInstructions-Dari.pdf

Dec 2023

Document

FITKitInstructions-Pashto.pdf

Dec 2023

Guidelines and Advice

Fear of Cancer Recurrence Guideline

Status: Current
ID: GL 19-7

Mar 2024

Document

basic-template

May 2024

Regimen

FLAG+IDA+VENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

ODB - General Benefit

filgrastim (biosimilars) - refer to ODB Formulary for details

Drugs Used:

venetoclax (Unfunded)

... Show more tags